AKBA Earnings

AKBA reported its FY2025Q3 earnings on 2025-11-10, showcasing a revenue of 58.77M against an estimate of 56.42M, resulting in a 4.16% surprise. The EPS was 0, surpassing the expected 0 by 0% . The stock experienced a -18.14% price change on the earnings day and a -13.73% change over the next five days, reflecting market reactions to the results.

Following AKBA's FY2025Q3 earnings announcement on 2025-11-10, the stock price moved by -18.14% on the day of the release. Over the subsequent five days, it saw a -13.73% change. Historically, AKBA's stock price tends to shift by an average of +7.66% in the 10 days leading up to earnings and +7.37% in the 10 days following, providing insight into potential market.

For 2025/Q4, analysts estimate AKBA’s annual revenue to reach 56.18M, while the EPS is projected at 0.00. These estimates reflect recent revisions, with revenue estimates revised Revenue No Change by 0% and EPS estimates Revise Upward by 23.74% over the past three months, indicating analyst expectation in the company’s performance.

The correlation between AKBA's stock price and earnings forecast revisions shows that positive revisions in revenue or EPS often strengthen the stock’s fundamentals. Over the past three months, revenue estimates for FY2025 were No Change by 0%, while EPS estimates moved Revise Upward by 23.74% . This trend suggests that price dips could present buying opportunities for investors.

Based on historical trends, AKBA's stock price typically moves by +7.66% in the 10 days before its earnings and +7.37% in the 10 days after. For the upcoming 2025/Q4 earnings, analysts expect an EPS of 0.00 and revenue of 56.18M.

The earnings call highlights significant patient access expansion for Vafseo, improved financial performance, and positive physician feedback on clinical data. Although there are operational challenges, strategies are in place to address them. The Q&A reveals enthusiasm for the product and progress in partnerships, despite some uncertainties. Overall, the company's optimistic revenue growth expectations, patient access expansion, and improved net income suggest a positive stock price movement over the next two weeks.